| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/13/2013 | EP2566863A1 Quinolylpiperazino substituted thiolactone compounds and process for the preparation thereof |
| 03/13/2013 | EP2566862A1 Benzofuranyl analogues as gpr119 modulators |
| 03/13/2013 | EP2566861A1 Modulators of fatty acid amide hydrolase |
| 03/13/2013 | EP2566860A1 Bicyclic heteroaryl compounds as gpr119 modulators |
| 03/13/2013 | EP2566859A2 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same |
| 03/13/2013 | EP2566856A2 Compounds and methods of treating brain disorders |
| 03/13/2013 | EP2566855A1 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| 03/13/2013 | EP2566854A2 Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
| 03/13/2013 | EP2566853A1 Tetrazolones as inhibitors of fatty acid synthase |
| 03/13/2013 | EP2566851A1 Combretastatin analogs for use in the treatment of cancer |
| 03/13/2013 | EP2566849A1 8-hydroxy-quinoline derivatives |
| 03/13/2013 | EP2566847A1 Novel immunomodulator and anti inflammatory compounds |
| 03/13/2013 | EP2566535A2 Releasing device for administering a bio-active agent |
| 03/13/2013 | EP2566513A1 Gfi1b modulation and uses thereof |
| 03/13/2013 | EP2566488A2 Povidone-iodine topical composition |
| 03/13/2013 | EP2566487A1 Ophthalmic composition |
| 03/13/2013 | EP2566486A1 Sulphated hyaluronic acid in combination with g-csf for use in mobilising blood stem cells |
| 03/13/2013 | EP2566485A1 Immunostimulatory compositions and methods of use thereof |
| 03/13/2013 | EP2566484A2 Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses |
| 03/13/2013 | EP2566483A1 Methods and agents for enhancing wound healing |
| 03/13/2013 | EP2566482A1 Progesterone receptor antagonists and uses thereof |
| 03/13/2013 | EP2566481A1 Aza-indole derivatives useful as modulators of faah |
| 03/13/2013 | EP2566480A2 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase |
| 03/13/2013 | EP2566479A1 Azaindazoles |
| 03/13/2013 | EP2566478A1 Pharmaceutical composition and method for treating hypertension |
| 03/13/2013 | EP2566477A1 Amino-quinolines as kinase inhibitors |
| 03/13/2013 | EP2566476A1 Nicotine-containing pharmaceutical compositions |
| 03/13/2013 | EP2566475A2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration |
| 03/13/2013 | EP2566474A2 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| 03/13/2013 | EP2566473A1 Dosage regimen of diaryl sulfide derivatives |
| 03/13/2013 | EP2566472A1 A pharmaceutical composition comprising aspirin and bisoprolol |
| 03/13/2013 | EP2566471A2 Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture |
| 03/13/2013 | EP2566470A1 Treatment of autoimmune diseases |
| 03/13/2013 | EP2566469A1 Combination therapy |
| 03/13/2013 | EP2566465A2 Stable rosuvastatin formulations |
| 03/13/2013 | EP2566464A1 Pharmaceutical formulations comprising pioglitazone and linagliptin |
| 03/13/2013 | EP2566463A1 Extended release thiocolchicoside tablets |
| 03/13/2013 | EP2566462A1 Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| 03/13/2013 | EP2566461A2 Solid tapentadol in non-crystalline form |
| 03/13/2013 | EP2566458A2 Pharmaceutical formulations compising cefuroxime axetil |
| 03/13/2013 | EP2566457A1 Topical pharmaceutical composition comprising heparin |
| 03/13/2013 | EP2566456A2 Triamcinolone acetonide formulations for treating dermatitis and psoriasis |
| 03/13/2013 | EP2566455A1 Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies |
| 03/13/2013 | EP2566454A1 Chitosan composition |
| 03/13/2013 | EP2566453A1 Novel ophthalmic compositions |
| 03/13/2013 | EP2566452A1 Melting tablet comprising a triptane or atypical neuroleptic |
| 03/13/2013 | EP2566451A1 Pharmaceutical compositions comprising cefditoren pivoxil |
| 03/13/2013 | EP2566450A2 Pharmaceutical compositions comprising cefetamet |
| 03/13/2013 | EP2566449A2 Pharmaceutical compositions comprising ceftibuten |
| 03/13/2013 | EP2566448A2 Efervescent formulations comprising cefdinir |
| 03/13/2013 | EP2566446A2 Novel low concentration meloxicam tablets |
| 03/13/2013 | EP2566335A1 Controlled release from macromolecular conjugates |
| 03/13/2013 | EP2566333A1 Identification of stabilizers of multimeric proteins |
| 03/13/2013 | EP2566331A1 Pharmaceutical compositions and methods of making same |
| 03/13/2013 | EP2566330A1 Nuclear receptor binding agents |
| 03/13/2013 | EP2566329A1 Process for synthesizing oxidized lactam compounds |
| 03/13/2013 | EP2566328A1 Indazoles |
| 03/13/2013 | EP2566327A1 Indoles |
| 03/13/2013 | EP2566326A1 Novel piperidine-flavan alkaloid compounds derived from african herb tea kinkeliba as anti-diabetic agents |
| 03/13/2013 | EP2566325A1 Compositions of small molecule therapeutics |
| 03/13/2013 | EP2489735A9 Aptamer capable of binding to viral hemorrhagic septicemia virus |
| 03/13/2013 | EP2291345B1 Co-crystals of duloxetine and naproxen |
| 03/13/2013 | CN202777133U Aspirin enteric controlled-release preparation |
| 03/13/2013 | CN1981776B Composition containing rare ginseng saponin, its production and usage |
| 03/13/2013 | CN1953967B Purification of progesterone receptor modulators |
| 03/13/2013 | CN1805966B Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| 03/13/2013 | CN102971424A High-affinity nucleic acid aptamers against sclerostin protein |
| 03/13/2013 | CN102971423A Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
| 03/13/2013 | CN102971415A Platelet-derived growth factor-BB production promoter, and mesenchymal stem cell production promoter, stem cell stabilizer and dermis regenerator each comprising same |
| 03/13/2013 | CN102971414A Treatment of bone fracture |
| 03/13/2013 | CN102971330A Metal complexes of thiourea and their derivatives as metal delivering anti-cancer and anti-inflammatory agents |
| 03/13/2013 | CN102971329A Pyrrolobenzodiazepines used to treat proliferative diseases |
| 03/13/2013 | CN102971327A Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
| 03/13/2013 | CN102971326A Imidazopyridazinyl compounds and their uses for cancer |
| 03/13/2013 | CN102971325A Compounds for the reduction of beta-amyloid production |
| 03/13/2013 | CN102971324A MTOR selective kinase inhibitors |
| 03/13/2013 | CN102971323A Heterocyclic compounds as JANUS kinase inhibitors |
| 03/13/2013 | CN102971322A Macrocyclic compounds as TRK kinase inhibitors |
| 03/13/2013 | CN102971321A Imidazopyrazines |
| 03/13/2013 | CN102971320A New azacyclic compounds |
| 03/13/2013 | CN102971318A Tetrahydrocarboline derivative |
| 03/13/2013 | CN102971317A Tetrahydro-pyrido-pyrimidine derivatives |
| 03/13/2013 | CN102971316A Fused bicyclic kinase inhibitors |
| 03/13/2013 | CN102971311A Bicyclic heteroaryl compounds as GPR119 modulators |
| 03/13/2013 | CN102971310A (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists |
| 03/13/2013 | CN102971308A Non-nucleoside reverse transcriptase inhibitors |
| 03/13/2013 | CN102971307A Piperidinyl pyrimidine amides as KV7 potassium channel openers |
| 03/13/2013 | CN102971306A Pyrazolopyridines as inhibitors of the kinase LRRK2 |
| 03/13/2013 | CN102971305A Heterocyclic antiviral compounds |
| 03/13/2013 | CN102971304A GPR119 agonist |
| 03/13/2013 | CN102971301A 6 - methyl - 4 - phenyl - 5 - ( phenyl or cycloalkyl) carbamoyl - 1,2,3, 4 - tetrahydropyrimidin- 2 - one derivatives as antitubercular agents |
| 03/13/2013 | CN102971300A Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
| 03/13/2013 | CN102971297A Method for preparing an intermediate of pitavastatin or of the salt thereof |
| 03/13/2013 | CN102971296A Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide |
| 03/13/2013 | CN102971294A Urethanes, ureas, amidines and related inhibitors of factor Xa |
| 03/13/2013 | CN102971293A Bipyridyl derivatives useful for the treatment of kinase-induced diseases |
| 03/13/2013 | CN102971291A Novel amide derivative and use thereof as medicine |
| 03/13/2013 | CN102971286A New cathepsin S protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions |
| 03/13/2013 | CN102971005A Diabetes therapy |
| 03/13/2013 | CN102970995A Stable antiseptic compositions and methods |